---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000022"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:58:56.167407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8

## Summary
- First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.
- Second tranche mandatory $80M at $1.716/share conditional on Phase 2b topline data for vidofludimus calcium in PMS (April 2025) and stock price/volume thresholds.
- Third tranche up to $80M at same price but cashless settlement possible; total gross proceeds $80M–$240M.
- Proceeds to fund vidofludimus calcium, IMU-856, and IMU-381 clinical development; first tranche extends cash runway into Q3 2025.

## SEC filing metadata
- accession: 0001193805-24-000022
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/0001193805-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000022
- JSON: https://secwatch.observer/filing/0001193805-24-000022.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.